The BioWorld Insider Podcast

0

One-on-one with medical innovators: Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us for a new conversation.

More
Recent Episodes
  • The importance of balancing AI and people in drug development
    May 27, 2025 – 21:11
  • Two CEOs discuss bracing for tariffs, NIH grant cuts and gifting China biopharma leadership position
    Apr 23, 2025 – 31:13
  • As biopharma investments stumble, med tech surges
    Mar 30, 2025 – 12:26
  • Mega money well spent? Mammoth mergers fall short of the dream
    Feb 24, 2025 – 19:13
  • Healing the health divide for women
    Nov 22, 2024 – 20:54
  • Modifi gets creative on the rocky road to a multibillion-dollar buyout
    Nov 13, 2024 – 23:56
  • A quantum leap into the future of drug development
    Oct 17, 2024 – 17:32
  • Gene and cell therapies will propel innovation, says Astellas CCO
    Oct 7, 2024 – 27:17
  • Capricor’s CEO pursues a BLA and talks rare disease
    Sep 27, 2024 – 15:50
  • The first half of 2024 was strong as M&As and financings dominate
    Jul 26, 2024 – 18:01
  • The cost of delays in development and sales: It’s probably not what you think
    Jul 17, 2024 – 16:44
  • ASCO preview: ADCs and radiotherapies at the forefront of this year’s conference
    May 30, 2024 – 13:11
  • Fibrobiologics walks the unconventional financing path
    May 15, 2024 – 18:16
  • Back to fundamentals: The latest numbers point to better times
    May 6, 2024 – 21:38
  • Mark McKenna storms back with Mirador and eyes the development landscape
    Apr 23, 2024 – 25:01
  • Biopharma execs seek to avoid pain points in AI integration
    Apr 16, 2024 – 19:19
  • Six biopharma executives consider a tough 2023 and are hopeful for a better 2024
    Dec 11, 2023 – 17:05
  • AI: driving drug development from effective to remarkable
    Sep 6, 2023 – 26:32
  • The struggle is real: The first half of 2023 was an uphill climb
    Aug 16, 2023 – 25:47
  • The biosimilars challenge to Humira revs up
    Jul 20, 2023 – 17:06
  • Preventing opioid overdoses with a smart patch
    Jun 5, 2023 – 23:20
  • Better times ahead for the biopharma sector? Could be, the new numbers say
    Apr 24, 2023 – 28:02
  • Radiopharmaceuticals: The next big disrupter?
    Apr 5, 2023 – 13:58
  • Cambrian carves out a new niche as it works to keep people from getting sick
    Feb 21, 2023 – 28:06
  • Rethinking obesity: Fitness may be more directly linked to health than weight
    Jan 30, 2023 – 21:23
  • Looking ahead to 2023: CEOs contemplate the new normal
    Dec 5, 2022 – 24:55
  • Psychedelic evolution: Mindset Pharma looks to change mental health treatment
    Sep 21, 2022 – 25:48
  • $1B+ biopharma deals keep values afloat, even amid muted volume
    Sep 8, 2022 – 28:20
  • Extending the human lifespan
    Jul 18, 2022 – 41:42
  • New therapies vie to change the fatal course of amyotrophic lateral sclerosis
    Jun 3, 2022 – 33:08
  • Biopharma’s correction? 2022 1Q investments are both up and down
    May 2, 2022 – 17:41
  • Who advises the CDC on big COVID decisions?
    Feb 23, 2022 – 24:27
  • Long COVID: Potentially the next public health crisis
    Feb 14, 2022 – 23:46
  • What happens when your inventor is an artificial intelligence?
    Dec 14, 2021 – 29:14
  • Another record year for biopharma financings bodes well for 2022
    Dec 9, 2021 – 18:41
  • Aduhelm’s hard lessons and what it means for other Alzheimer’s drugs
    Dec 9, 2021 – 32:30
  • Supply Chain Geeky: Managing through the challenges of COVID-19 with an eye to what’s at stake
    Dec 9, 2021 – 24:00
  • Regulatory Gemish: COVID-19’s big impacts on the FDA and beyond
    Dec 9, 2021 – 28:54
  • Reality check: How did industry develop COVID-19 vaccines and drugs so fast?
    Oct 26, 2021 – 16:39
  • Merck’s new COVID-19 pill will save lives, but at what price?
    Oct 18, 2021 – 28:16
  • Newly approved cervical cancer drug Tivdak gives patients a new option
    Sep 24, 2021 – 18:01
  • DNA vaccines: a better path to taming the pandemic?
    Sep 17, 2021 – 26:08
  • Rising to the COVID-19 challenge, clinical trials evolve
    Sep 2, 2021 – 24:50
  • A ‘Revolution’ in drugging the undruggable hits a speed bump but motors on
    Aug 20, 2021 – 31:28
  • As dementia cases grow, biomarkers and new therapies key to unlocking treatment
    Jul 30, 2021 – 34:05
  • As biopharma deals keep pace, M&A volumes languish
    Jul 9, 2021 – 14:22
  • Iteos brings Glaxosmithkline a third checkpoint-targeting antibody in a $2B deal
    Jun 16, 2021 – 12:33
  • Finally, a new medicine for Alzheimer’s disease
    Jun 10, 2021 – 09:17
  • The BioWorld Insider Podcast - trailer
    Jun 4, 2021 – 00:35
Recent Reviews
Disclaimer: The podcast and artwork on this page are property of the podcast owner, and not endorsed by UP.audio.